Metsera, Inc. (MTSR) Market Cap
Metsera, Inc. has a market capitalization of $7.43B.
Price: $70.50
▼ -0.25 (-0.35%)
Market Cap: 7.43B
NASDAQ · time unavailable
CEO: Christopher Whitten Bernard
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2025-01-31
Website: https://metsera.com
Metsera, Inc. (MTSR) - Company Information
Market Cap: 7.43B|Sector: Healthcare
Company Profile
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Analyst Sentiment
From 3 Active Polls
1Y Forecast: $55.50
▼ -21.3% Potential Upside
Consensus Target Metrics
Low Bound
$54
Median
$56
High Bound
$57
Average
$56
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 30, 2024 | Dec 31, 2023 |
| Market Cap ($M) | 7,429 | 5,496 | 2,984 | 2,830 | 2,730 | 1,324 | 1,324 | 1,324 | 1,324 |
| Enterprise Value ($M) | 6,983 | 5,051 | 2,454 | 2,251 | 2,388 | 1,142 | — | — | — |
| Price to Earnings Ratio (P/E) | -23.55 | -11.82 | -10.86 | -9.24 | -12.91 | -3.02 | -12.38 | -16.64 | -27.87 |
| Price/Earnings-to-Growth Ratio (PEG) | — | — | — | — | — | — | — | — | — |
| Price to Sales Ratio (P/S) | — | — | — | — | — | — | — | — | — |
| Price to Book Ratio (P/B) | 21.96 | 16.30 | 6.64 | 5.60 | 9.50 | 10.20 | — | — | — |
| Price to Free Cash Flow Ratio (P/FCF) | -32.08 | -67.26 | -50.44 | -52.07 | -75.06 | -46.77 | -67.40 | -83.92 | -99.45 |
| Enterprise Value to Sales (EV/Sales) | — | — | — | — | — | — | — | — | — |
| Enterprise Value to EBITDA (EV/EBITDA) | -17.73 | -43.46 | -35.74 | -29.43 | -18.01 | -10.39 | — | — | — |
| Debt to Equity Ratio | 1.13 | 0.01 | 0.00 | 0.02 | 0.03 | 0.05 | — | — | — |
📘 Full Research Report
AI-Generated Research: This report is for informational purposes only.
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for MTSR.
IP Group shares jump 9% as Metsera deal drives return to growth
Shares in IP Group PLC (LSE:IPO) rose 9% to 53.5p on Monday after the company reported net asset value per share climbing to 110.4p, with total NAV reaching £975.1 million. The recovery was driven largely by Pfizer's acquisition of Metsera, a biotechnology company developing obesity treatments.
Metsera Inc. (NASDAQ:MTSR) Given Average Recommendation of “Hold” by Brokerages
Metsera Inc. (NASDAQ: MTSR - Get Free Report) has been given a consensus rating of "Hold" by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company.
Pfizer Completes Acquisition of Metsera
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. “This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth ther.
Metsera shareholders vote for $10 billion acquisition by Pfizer
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk.
Why Metsera's Share Price Is Plummeting This Week
Metsera was the target of a bidding war by pharma giants. The company has an innovative obesity drug candidate.
Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers
On this episode of Stock Movers with Lisa Mateo: - Metsera (MTSR) shares tank in premarket trading after Novo Nordisk A/S declined to further raise its offer for the US maker of an experimental weight-loss drug, bringing a bidding war with Pfizer Inc. to an end. Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday after Pfizer matched its latest offer in a takeover battle that had caused concern the bidders might be overpaying for an unproven asset.
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical development and manufacturing.
5 Things to Know Before the Stock Market Opens
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President Donald Trump has proposed issuing $2,000 “dividend” checks to Americans that would be funded by revenue from tariffs; AI data center firm CoreWeave (CRWV) is set to release its quarterly results after the closing bell today; and shares of Metsera (MTSR) are plunging after the weight-loss drug maker announced that it would be acquired by Pfizer (PFE) after a bidding war with Novo Nordisk (NVO). Here's what you need to know today.
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1.5% on Monday.
Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle
Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.
Novo Nordisk shares rise after dropping Metsera bid
Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its bid for U.S. weight loss drug company Metsera, ending a bidding war with rival Pfizer.
Wall Street Brunch: Here Come The 13Fs
13F filings this week will reveal hedge fund and institutional moves, offering insight into smart money positioning amid recent market highs. Earnings season is winding down, with 90% of S&P 500 companies reporting; most beat estimates, but guidance remains cautious.
📊 AI Financial Analysis
Powered by StockMarketInfo"MTSR currently reports zero revenue and a significant net income loss of $116.2M for the most recent quarter. With total assets of $567.6M and total liabilities of $230.5M, the company maintains a solid equity position of $337.2M, further strengthened by a net debt of -$445.6M, indicating a strong cash position relative to its liabilities. However, it recorded an operating cash flow loss of $81.7M, reflecting negative cash flow quality and no dividends paid to shareholders. As a pre-revenue entity, MTSR's growth prospects are clouded by its current operational challenges, which translate into a high degree of risk. Despite no current market price listed or 1-year performance change data, analysts project a price target range, with a consensus of $55.5 per share. Overall, MTSR presents notable profitability concerns and lacks effective shareholder returns due to its financial losses and absence of revenue, making it a high-risk consideration for investors."
Revenue Growth
Company has zero revenue as it is in a pre-revenue stage.
Profitability
Significant net loss of $116.2M indicates poor profitability.
Cash Flow Quality
Negative cash flow of $81.7M highlights cash flow concerns.
Leverage & Balance Sheet
Strong balance sheet with total equity of $337.2M and negative net debt.
Shareholder Returns
No dividends paid and negative financial performance.
Analyst Sentiment & Valuation
Projected price target suggests potential, but high risk remains.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for MTSR.